LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.17 7.34

Buy Sell

Overview

Share price change

24h

Current

Min

1.06

Max

1.17

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+335.71% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	-6.17
Previous close	1.17

News Sentiment

By Acuity

50%

149 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2026, 23:47 UTC

Hot Stocks

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 lut 2026, 22:59 UTC

Earnings

Acquisitions, Mergers, Takeovers

Grab Holdings to Buy U.S.-Based Stash Financial

11 lut 2026, 23:54 UTC

Earnings

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 lut 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 lut 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 lut 2026, 23:49 UTC

Earnings

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 lut 2026, 23:45 UTC

Earnings

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 lut 2026, 23:42 UTC

Earnings

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 lut 2026, 23:41 UTC

Earnings

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 lut 2026, 23:40 UTC

Earnings

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 lut 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 lut 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 lut 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 lut 2026, 22:59 UTC

Earnings

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 lut 2026, 22:58 UTC

Earnings

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 lut 2026, 22:57 UTC

Earnings

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 lut 2026, 22:54 UTC

Earnings

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 lut 2026, 22:53 UTC

Earnings

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:47 UTC

Earnings

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 lut 2026, 22:23 UTC

Earnings

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 lut 2026, 22:22 UTC

Earnings

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 lut 2026, 22:19 UTC

Earnings

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 lut 2026, 22:18 UTC

Earnings

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 lut 2026, 22:16 UTC

Earnings

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

335.71% upside

12 Months Forecast

Average 4.88 USD 335.71%

High 8 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

149 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.